Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The Board believes Appio's deep knowledge of the business, global leadership experience and longstanding connection to Bausch + Lomb position him well to build on the company's momentum and lead its next phase of growth.

  60% confidence

• Saunders believes Bausch + Lomb is stronger, more focused and better positioned for the future, with a clearer strategy, a more robust pipeline and significant opportunities ahead.

  60% confidence

• Bausch Health (excluding Bausch + Lomb) has delivered 13 consecutive quarters of year-over-year growth in revenue and adjusted EBITDA (non-GAAP) under Appio's leadership.

  60% confidence

• Appio embraces the opportunity to lead Bausch + Lomb, which is built on its people, portfolio and commitment to customers and patients, and is well positioned to build on its momentum and deliver sustainable growth.

  60% confidence

• Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D guidance, based on preliminary third-quarter results.

  60% confidence

Cited in these Via News reports

• Dow Is Cutting Its Way Back, Union Pacific Is Betting on a Merger: What Two Industrial Giants Said on 22 October →